PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Myotubular myopathy (MTM) is a devastating pediatric neuromuscular disorder of phosphoinositide (PIP) metabolism resulting from mutations of the PIP phosphatase MTM1 for which there are no treatments. We have previously shown phosphatidylinositol-3-phosphate (PI3P) accumulation in animal models of MTM. Here, we tested the hypothesis that lowering PI3P levels may prevent or reverse the MTM disease process. To test this, we targeted class II and III PI3 kinases (PI3Ks) in an MTM1-deficient mouse model. Muscle-specific ablation of Pik3c2b, but not Pik3c3, resulted in complete prevention of the MTM phenotype, and postsymptomatic targeting promoted a striking rescue of disease. We confirmed this genetic interaction in zebrafish, and additionally showed that certain PI3K inhibitors prevented development of the zebrafish mtm phenotype. Finally, the PI3K inhibitor wortmannin improved motor function and prolonged lifespan of the Mtm1-deficient mice. In all, we have identified Pik3c2b as a genetic modifier of Mtm1 mutation and demonstrated that PIK3C2B inhibition is a potential treatment strategy for MTM. In addition, we set the groundwork for similar reciprocal inhibition approaches for treating other PIP metabolic disorders and highlight the importance of modifier gene pathways as therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790 · cited 1×
“org Volume 126 Number 9 September 2016 Introduction Phosphoinositides (PIPs) are low-abundance phospholipids responsible for the regulation of myriad cellular processes, including membrane trafficking and intracellular signaling cascades (1, 2).”
BackgroundComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741 · cited 7×
“defined a complicated interplay between FIG4, MTMR2, and the regulation of PI(3,5)P2 (30, 31).”
BackgroundInfluentialLaporte, J., Hu, L. J., Kretz, C., Mandel, J.-L., Kioschis, P., Coy, J. F., Klauck, S. M., Poustka, A., & Dahl, N. (1996) · Nature Genetics · doi:10.1038/ng0696-175 · Cited by 639 · cited 15×
“We found that while Pik3c3 deletion Myotubular myopathy (MTM) is a devastating pediatric neuromuscular disorder of phosphoinositide (PIP) metabolism resulting from mutations of the PIP phosphatase MTM1 for which there are no treatments.”
BackgroundInfluentialDeleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS
Chow, C. Y., Landers, J. E., Bergren, S. K., Sapp, P. C., Grant, A. E., Jones, J. M., Everett, L., Lenk, G. M., McKenna-Yasek, D. M., Weisman, L. S., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.010 · Cited by 407
Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007523 · Cited by 173 · cited 1×
“org Volume 126 Number 9 September 2016 (19), PIK3C2B inhibition is an extremely attractive target that may work either as a monotherapy or as a complement to existing efforts under investigation such as MTM1 gene therapy and MTM1 enzyme replacement therapy (26, 27).”
BackgroundSelf-citationDefective Autophagy and mTORC1 Signaling in Myotubularin Null Mice
Fetalvero, K. M., Yu, Y., Goetschkes, M., Liang, G., Valdez, R. A., Gould, T., Triantafellow, E., Bergling, S., Loureiro, J., Eash, J., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01075-12 · Cited by 96 · cited 1×
“that Mtm1 KO mice have improved muscle mass when treated with an mTOR inhibitor (AZD8055) that increases autophagic flux (37).”
BackgroundLoss of Fig4 in both Schwann cells and motor neurons contributes to CMT4J neuropathy
Vaccari, I., Carbone, A., Previtali, S. C., Mironova, Y. A., Alberizzi, V., Noseda, R., Rivellini, C., Bianchi, F., Del Carro, U., D'Antonio, M., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu451 · Cited by 49
Cited by
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Phosphoinositides as membrane organizers
Posor, Y., Jang, W., & Haucke, V. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00490-x · Cited by 469
Congenital myopathies: disorders of excitation–contraction coupling and muscle contraction
Jungbluth, H., Treves, S., Zorzato, F., Sarkozy, A., Ochala, J., Sewry, C., Phadke, R., Gautel, M., & Muntoni, F. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.191 · Cited by 280
Phosphoinositides, Major Actors in Membrane Trafficking and Lipid Signaling Pathways
De Craene, J.-O., Bertazzi, D., Bär, S., & Friant, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030634 · Cited by 204
“myopathy phenotypes in a Mtm1 disease mouse model, and inhibition of the PIK3C2B kinase activity after appearance of myopathy symptoms promoted a striking rescue in the zebrafish model [48].”
BackgroundNovel roles of phosphoinositides in signaling, lipid transport, and disease
Hammond, G. R. V., & Burke, J. E. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.12.007 · Cited by 203
“The development of PIK3C2B inhibitors may be useful as MTM therapeutics [82], but surprisingly it has been found in mouse models that the clinically approved estrogen receptor inhibitor tamoxifen can ameliorate some of the symptoms of MTM [83].”
Background
Metadata
- Authors
- Sabha, N., Volpatti, J. R., Gonorazky, H., Reifler, A., Davidson, A. E., Li, X., Eltayeb, N. M., Dall’Armi, C., Di Paolo, G., Brooks, S. V., Buj-Bello, A., Feldman, E. L., & Dowling, J. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-22
- Volume
- 126
- Issue
- 9
- Pages
- 3613-3625
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2513851588
- Cited by
- 106
- References
- 9
- FWCI
- 12.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.